Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Nov 14, 2022 4:17pm
308 Views
Post# 35097829

sad sad sad

sad sad sadAnother stellar presentation by ONCY. Does Matt forget that he is on camera the whole time... he just looks desperate these days. At least Dr Hofmeister presented reasonably well today.

Without wanting to deflate Noteable and Canadafan's bubbles too much. They may have you believing that the company will be sold for billions... really..? LOOK at the share price and volume... The company is closer to running a Phase III than it has been for years, so WHERE is the interest?

Well, they have postponed a Phase III in mBC because nobody would pay for it, come on... they only had to repeat the results of IND-213 in a larger randomised Phase III (the words of the FDA) and they could have had a marketable product by now, which would have been paying for them to test the addition of a CPI. But no... they monkeyed around for a few more years instead. WHERE is the Phase III from Adlai Nortye ? Even they have removed it from their presentations.

Folks the pps for this will ONLY move, on a partnership. ONCY knows it cannot afford to run a phase III itself. According to Matt (from 2018), Roche only needed the Aware-1 data to pull the trigger on a deal. So WHAT are Roche waiting for ??

By trading this pos over the 15 years I've been in the stock, I'm now down only 40%..!! But I'm done, there are far better opportunities out there with far less risk. If there were any interest in this company, it's stock price wouldn't be down 96% since they started..!! 

GLTA

p.s. the patient in the GOBLET trial who had a CR, had metastases to the Lymph Node, NOT the liver as was posted earlier.
<< Previous
Bullboard Posts
Next >>